Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors

In Vivo

Volumn 16, Issue 6, 2002, Pages 541-550

  Lovgren, Todd R ^a   Tarantolo, Stefano R ^b   Evans, Cody ^a   Kuszynski, Charles A ^b   Joshi, Shantaram S ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Colony stimulating factors; Cord blood; Effector cells; IL 15; Non specific killing

Indexed keywords

CD56 ANTIGEN; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; PERFORIN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; GAMMA INTERFERON; MEMBRANE PROTEIN; MESSENGER RNA; PORE FORMING CYTOTOXIC PROTEIN;

ACCESSORY CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; METASTASIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; UMBILICAL CORD BLOOD; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; FEMALE; FETUS BLOOD; GENETICS; IMMUNOLOGY; LIVER; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; COLONY-STIMULATING FACTORS; CYTOTOXICITY, IMMUNOLOGIC; DRUG COMBINATIONS; FAS LIGAND PROTEIN; FEMALE; FETAL BLOOD; HUMANS; INTERFERON TYPE II; INTERLEUKIN-15; LEUKOCYTES, MONONUCLEAR; LIVER; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0036865247     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wagner JE, Kerman NA, Steinbuch M, Broxmeyer HE and Gluckman E: Allogeneic sibling umbilical cord blood transplantation in children with malignant and nonmalignant disease. Lancet 346: 214-219, 1995.
2. Pahwa RN, Fleischer A, Than S and Good R: Successful hematopoietic reconstitution with transplantation of erythrocyte-depleted allogeneic human umbilical cord blood cells in a child with leukemia. Proc Natl Acad Sci USA 91: 4485-4488, 1994.
3. Kutzberg JK, Langhlin M, Graham ML, Smith C, Olson JF and Rubenstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335: 157-166, 1996.
4. Leary AG and Ogawa M: Blast cell colony assay for umbilical cord blood and adult bone marrow progenitors. Blood 96: 953-956, 1987.
5. Cairo MS and Wagner JE: Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 90: 4665-4678, 1997.
6. Gardiner CM, O'Meara A and Reen DJ: Differential cytotoxicity of cord blood and bone marrow-derived natural killer cells. Blood 91: 207-213, 1998.
7. Apperley JF: Umbilical cord blood progenitor cell transplantation. Bone Marrow Transplant 14: 187-196, 1994.
8. Joshi SS, Tarantolo S, Kuszynski C and Kessinger A: Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer. Clinical Cancer Res 6: 4351-4358, 2000.
9. Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R and De La Garza J: Medical castration produced by the GnRh analogue leuprolide to treat metastatic breast cancer. J Clin Oncol 3: 1068-1072, 1985.
10. Wingard JR, Moreb JS and Gaa RI: High-dose chemotherapy with autologous stem cell rescue as a treatment modality for breast cancer. Breast J 5: 308-318, 1999.
11. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K and Knutson KL: Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 5: 1347-1350, 2000.
12. Disis ML, Grabstein KH, Sleath PR and Cheever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5: 1289-1297, 1999.
13. Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J and Cohen EP: Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
14. Apostolopoulos V, Xing PX and McKenzie IF: Murine immune response to cells transfected with human MUC-1: Immunization with cellular and synthetic antigens. Can Res 54: 5186-5193, 1994.
15. Harris DT: In Vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 15: 17-23, 1995.
16. Dempke W, Von Poblozki A, Grothey A and Schmoll HJ: Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res 20: 5155-5164, 2000, review.
17. Joshi SS, Tilden PA, Jackson JD and Sharp JG: Cell surface properties associated with malignancy of RAW1 17 large cell lymphoma cells. Cancer Res 47: 3551-3557, 1987.
18. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR, Kuszynski CA, Pirruccello SJ, Bishop MR and Kessinger S: Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. Int J Oncol 13: 791-799, 1998.
19. Dempke W, Von Poblozki A, Grothey A and Schnoll HJ: Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res 20: 5155-5164, 2000.
20. McNiece 1, Jones R, Bearman SI, Cagnoni P, Nietoi Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J and Shpall EJ: Ex vivo expanded peripheral blood progenitor cells provie rapid neutrophils recovery after high-dose chemotherapy in patients with breast cancer. Blood 96: 3001-3007, 2000.
21. Sasaki E, Tashiro T, Kuroki M, Seki M, Miyazaki Y, Maesaki S, Tomono K, Kadota J and Kohno S: Effects of macrophage colony-stimulating factor (M-CSF) on antifungal activity of mononuclear phagocytes against Trichosporon asahii. Clin Exp Immunol 119: 293-298, 2000.
22. Liles WC: Immunomodulatroy approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 16: 11-17, 2001.
23. Westerman J, Reich G, Kopp J, Haus U, Dorken B and Pezzutto A: Granulocyte macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: A pilot study. Cancer Immunol Immunother 49: 613-620, 2001.
24. Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G and Francini G: Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2 results from a phase lb clinical trial. Eur J Cancer 37; 892-902, 2001.
25. Sosmann A, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, Van Besien K, Devine S, Stock W, Peace D, Chen Y Long C, Gustin D, Viana M and Hoffman R: Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: Expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol 19: 634-644, 2001.
26. Meehan KR, Wui A, Hassan R, Miao Y, Chawla J, Slack R, Gehan E and Herscowitz HB: Ex vivo cytokine activation of peripheral blood stem cells: A potential role for adoptive cellular immunotherapy. J Hematotherapy & Stem Cell Res 10: 283-290, 2001.